Comparing Citrate- Versus Acetate-Based Dialysate for Better Blood Pressure Stability During Intermittent Hemodialysis in Intensive Care

What this Trial Is About

Researchers are comparing two types of dialysate used during intermittent hemodialysis IHD sessions in intensive care units ICU to see which one better supports stable blood pressure. The study focuses on patients with acute kidney failure who are at risk for intradialytic hypotension, a common problem during dialysis that can affect recovery and survival. This trial evaluates citrate-based dialysate against the more common acetate-based dialysate to determine which provides better hemodynamic tolerance and dialysis effectiveness. Participants will be randomly assigned to receive IHD using either acetate-based or citrate-based dialysate. Both types are approved for routine use, but citrate dialysate may reduce episodes of low blood pressure during dialysis. The study will monitor treatment sessions up to 28 days, comparing how often hypotension occurs and other health outcomes like mortality, ICU stay length, kidney function recovery, and dialysis efficiency. Throughout the study, patients will undergo regular assessments including vital signs, blood tests for kidney function and electrolytes, and measurement of dialysis adequacy. Researchers will track the number of dialysis sessions with hemodynamic instability and evaluate recovery markers such as urine output and organ function scores. Safety and effectiveness will be observed during the ICU stay and up to day 28, with data collected on ventilation use, medication needs, and hospital length of stay.

Improved Hemodynamic Tolerance of Intermittent Hemodialysis Sessions in Intensive Care Unite Using Citrate- vs Acetate-based Dialysate